Dr. Reddy’s Laboratories gets USFDA nod to launch Eszopiclone Tablets C-IV

Dr. Reddy’s Laboratories has launched Eszopiclone Tablets (C-IV) 1 mg, 2 mg and 3 mg, a therapeutic equivalent generic version of LUNESTA (eszopiclone) tablets C-IV in the US market on April 15, 2014, following the approval by the United States Food & Drug Administration (USFDA). Dr. Reddy’s Eszopiclone Tablets (C-IV) 1 mg is available in bottle counts of 30. Eszopiclone Tablets (C-IV) 2 mg and 3 mg are available in bottle counts of 100. According to IMS Health, the LUNESTA (eszopiclone) tablets C-IV brand and generic combined had US sales of approximately $887 million MAT for the most recent twelve months ending in January 2014. Dr. Reddy’s is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.